相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?
Arpit Rao et al.
CANCERS (2022)
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration- resistant prostate cancer: a randomised, double-blind, phase 2 trial
Fred Saad et al.
LANCET ONCOLOGY (2022)
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double- blind, phase 2 trial (vol 23, pg 1297, 2022)
B. Bychkovsky et al.
LANCET ONCOLOGY (2022)
Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference
Yu-Ke Fu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2022)
Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
Norman J. Maitland
CANCERS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Prostate cancer
Richard J. Rebello et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
Katia A. Mesquita et al.
CANCERS (2021)
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
Tae Jin Kim et al.
BIOMOLECULES (2021)
Prostate Cancer Radiogenomics-From Imaging to Molecular Characterization
Matteo Ferro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer
Xiao Lu et al.
ONCOGENE (2020)
Inhibition of FEN1 Increases Arsenic Trioxide-Induced ROS Accumulation and Cell Death: Novel Therapeutic Potential for Triple Negative Breast Cancer
Xing Xin et al.
FRONTIERS IN ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
Lisanne Mout et al.
BRITISH JOURNAL OF CANCER (2020)
Biological and clinical significance of flap endonuclease-1 in triple-negative breast cancer: Support of metastasis and a poor prognosis
Lu Xu et al.
ONCOLOGY REPORTS (2020)
Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression
Jie Luo et al.
CANCER LETTERS (2019)
Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1
Y. Wang et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
Nicholas G. Nickols et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update
Giuseppe Lucarelli et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy
Gergana E. Stoykova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Abiraterone in High- and Low-risk Metastatic Hormone-sensitive Prostate Cancer
Alex P. Hoyle et al.
EUROPEAN UROLOGY (2019)
miR-193b Increases the Chemosensitivity of Osteosarcoma Cells by Promoting FEN1-Mediated Autophagy
Suwei Dong et al.
ONCOTARGETS AND THERAPY (2019)
Overexpression of Flap Endonuclease 1 Correlates with Enhanced Proliferation and Poor Prognosis of Non-Small-Cell Lung Cancer
Keqiang Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2018)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Noel Clarke et al.
LANCET ONCOLOGY (2018)
Lipid pathway deregulation in advanced prostate cancer
Laura Galbraith et al.
PHARMACOLOGICAL RESEARCH (2018)
Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer
Niranjan J. Sathianathen et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer
Lingfeng He et al.
MOLECULAR ONCOLOGY (2017)
Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells
Josef Mang et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
Jacky K. Leung et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
Barbara Kahn et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schroder et al.
LANCET (2014)
Flap Endonuclease 1
Lata Balakrishnan et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82 (2013)
Molecular aspects of cancer cell resistance to chemotherapy
Magali Rebucci et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer
Carlo Buonerba et al.
FUTURE ONCOLOGY (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
William R. Polkinghorn et al.
CANCER DISCOVERY (2013)
Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
David J. Mulholland et al.
CANCER RESEARCH (2012)
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Vincenzo Pagliarulo et al.
EUROPEAN UROLOGY (2012)
Sequential Posttranslational Modifications Program FEN1 Degradation during Cell-Cycle Progression
Zhigang Guo et al.
MOLECULAR CELL (2012)
The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer
A. Urbanucci et al.
ONCOGENE (2012)
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Meng-Lei Zhu et al.
CANCER RESEARCH (2010)
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Lu Gan et al.
CANCER RESEARCH (2009)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
P. J. Roberts et al.
ONCOGENE (2007)
Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score
John S. Lam et al.
BJU INTERNATIONAL (2006)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
分享论文
